Citigroup’s Akebia Therapeutics AKBA Stock Holding History

Citigroup’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-3,478	Closed	-$22K	–	7578
2019 Q4	$22K	Hold	3,478	–	–	﹤0.01%	6884
2019 Q3	$14K	Sell	3,478 -1,147	-25%	-$4.92K	﹤0.01%	6902
2019 Q2	$22K	Sell	4,625 -9,357	-67%	-$53.2K	﹤0.01%	7033
2019 Q1	$115K	Buy	13,982 +2,845	+26%	+$19.5K	﹤0.01%	5603
2018 Q4	$62K	Buy	+11,137	New	+$87.2K	﹤0.01%	6050

Other funds holding AKBA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Citigroup's AKBA Position: Q1 2026 in Review

Citigroup increased its Akebia Therapeutics (AKBA) stake by 17% in Q1 2026, buying an estimated $575K and bringing the position to 2,854,586 shares worth $3.97M. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

Citigroup first reported a position in AKBA in Q2 2014 and has held it in 48 quarters since. The position peaked at $8.26M in Q2 2020. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

Citigroup held 2,854,586 shares of Akebia Therapeutics worth $3.97M as of Q1 2026.
Citigroup bought 418,383 Akebia Therapeutics shares in Q1 2026, an estimated $575K.
Akebia Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #2140 holding.
Citigroup first reported a position in Akebia Therapeutics in Q2 2014 and has held it in 48 quarters since.
Citigroup's Akebia Therapeutics position peaked at $8.26M in Q2 2020.
171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.